New resource available view now
New resource available view now
Recent Post
Related Posts
POTOMAC, MD December 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer’s disease, today
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer’s Agitation Trial
POTOMAC, MARYLAND – December 09, 2025 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for
IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer’s Disease
New Caregiver Resource Showcases Expert Contributions and Reinforces IGC Pharma’s Leadership in Alzheimer’s Innovation
POTOMAC, MARYLAND – November 25, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for
POTOMAC, MARYLAND / November 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer’s disease,